Price regulation applied to 13 high-priced essential medicines has produced an estimated saving of Rs. 5.7 billion for the government, the National Medicines Regulatory Authority said on Thursday.
NMRA Chairman Dr. Ananda Wijewickrema disclosed the figure at a media briefing in Colombo, the Daily Mirror reported. He said the estimate was calculated on the basis of the price caps introduced for those 13 medicines.
What the figure does and does not tell you
The NMRA is the statutory regulator that sets maximum retail prices for medicines in Sri Lanka. A saving attributed to the government, rather than to patients, points to reduced state procurement cost — but the Authority’s account as reported does not spell out the basis of the calculation.
Several things are left open. The briefing as reported does not name the 13 medicines, state the period over which the Rs. 5.7 billion accrued, give the size of the price reductions, or explain whether the figure is measured against pre-regulation prices or against what the state would otherwise have paid. It also does not separate savings to government procurement from savings to households buying the same drugs at a pharmacy counter.
Those details matter because the headline number is an estimate of avoided cost, not an audited outturn.
Context
Medicine pricing and supply have been persistent pressure points. In September the Health Minister told Parliament that 33 of 618 essential medicines were out of stock, and the Consumer Affairs Authority has run repeated enforcement sweeps against pharmacies, raiding 471 outlets over the course of this year.
Price regulation sits awkwardly between those two problems: caps reduce what the state and patients pay, while importers have argued that controlled prices discourage supply of particular products.
No other verified newsroom had carried the Rs. 5.7 billion figure at the time of writing, and the NMRA had not published a release setting out the underlying calculation.
